Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (AZN) and Daiichi Sankyo reported DESTINY-Breast05 Phase 3 results showing ENHERTU reduced the risk of invasive disease recurrence or death by 53% (HR=0.47; 95% CI 0.34–0.66; p<0.0001) versus T-DM1 as post-neoadjuvant therapy in high-risk HER2+ early breast cancer.
Three-year IDFS was 92.4% for ENHERTU vs 83.7% for T-DM1; three-year DRFI was 93.9% vs 86.1%. OS was immature (2.9% mature; HR=0.61). Safety was consistent with known profile: grade ≥3 TEAEs ~50.6% (ENHERTU) vs 51.9% (T-DM1); ILD occurred in 9.6% (ENHERTU) with two adjudicated grade 5 events (0.2%).
ENHERTU (AZN) showed a statistically significant improvement in neoadjuvant pathologic complete response (pCR) in DESTINY-Breast11: 67.3% vs 56.3% with ddAC-THP (Δ11.2%; 95% CI 4.0-18.3; p=0.003).
ENHERTU followed by THP also produced higher RCB (0+I) rates (81.3% vs 69.1%) and consistent pCR gains across HR+ and HR– subgroups. Safety was described as favorable versus ddAC-THP with lower rates of grade ≥3 TEAEs (37.5% vs 55.8%), serious AEs (10.6% vs 20.2%), treatment interruptions (37.8% vs 54.5%) and left ventricular dysfunction (1.3% vs 6.1%).
Event-free survival was immature (4.5% maturity) with an early trend favoring ENHERTU (HR=0.56). The ENHERTU monotherapy arm was closed early; a supplemental BLA for ENHERTU followed by THP is under FDA review.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo reported DESTINY-Breast11 Phase III results showing neoadjuvant ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP produced a pCR rate of 67.3% vs 56.3% with a ΔpCR of +11.2% (95% CI 4.0–18.3), p=0.003. Improvements were seen in HR-positive (61.4% vs 52.3%) and HR-negative (83.1% vs 67.1%) subgroups.
Resection outcomes showed RCB 0+I 81.3% vs 69.1%. Safety favored ENHERTU with lower Grade ≥3 AEs (37.5% vs 55.8%), serious AEs (10.6% vs 20.2%) and left ventricular dysfunction (1.3% vs 6.1%). EFS was immature (4.5% maturity) with an early HR 0.56 (95% CI 0.26–1.17). A supplemental BLA is under FDA review.
AstraZeneca (NYSE:AZN) announced on October 17, 2025 that TEZSPIRE (tezepelumab‑ekko) received FDA approval for add‑on maintenance treatment of adults and pediatric patients aged 12+ with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
Approval was based on the Phase III WAYPOINT trial showing statistically significant reductions in nasal polyp severity, near‑elimination of the need for surgery and reduced systemic corticosteroid use versus placebo. TEZSPIRE is the first biologic targeting TSLP approved for CRSwNP. Regulatory applications are under review in the EU, China, Japan and other countries.
AstraZeneca (AZN) and Daiichi Sankyo reported initial results from a TROPION-PanTumor03 sub-study showing DATROWAY (datopotamab deruxtecan) plus rilvegostomig produced a confirmed objective response rate (ORR) of 68.2% (95% CI: 45.1–86.1) and disease control rate (DCR) of 95.5% (80% CI: 83.4–99.5) in cisplatin-ineligible first-line metastatic urothelial cancer (n=22).
In the second-line, previously platinum-treated/immunotherapy-naïve cohort (n=18), ORR was 38.9% (95% CI: 17.3–64.3) and median progression-free survival (PFS) was 12.5 months (95% CI: 4.2–NR). Median duration of response was not reached in either cohort. Safety was consistent with known profiles: grade ≥3 treatment-related adverse events occurred in 18.2% (first-line) and 38.9% (second-line); adjudicated ILD events were 1 (4.5%) and 2 (11.1%), respectively.
AstraZeneca (NYSE:AZN) reported that the POTOMAC Phase III trial met its primary endpoint: adding one year of IMFINZI (durvalumab) to BCG induction and maintenance reduced the risk of high-risk non-muscle-invasive bladder cancer recurrence or death by 32% (DFS HR 0.68; 95% CI 0.50-0.93; P=0.0154) with median follow-up of 60.7 months. Estimated 24-month DFS rates were 86.5% (IMFINZI+BCG) vs 81.6% (BCG). OS was not formally powered; descriptive OS HR was 0.80 (95% CI 0.53-1.20) at 65.6 months. Grade 3‑4 adverse events occurred in 34% (IMFINZI arm) vs 17% (BCG). Results presented at ESMO 2025 and published in The Lancet.
AstraZeneca (NYSE:AZN) announced results from the MATTERHORN Phase III trial showing a perioperative IMFINZI (durvalumab) plus FLOT regimen reduced the risk of death by 22% versus chemotherapy alone (HR 0.78; 95% CI 0.63-0.96; P=0.021) in resectable Stage II–IVA gastric and gastroesophageal junction cancer. Median OS was not reached in either arm at data cut-off Sept 1, 2025. Estimated 3-year OS was 69% with IMFINZI-FLOT versus 62% with FLOT alone. Prior EFS analysis showed a 29% reduction in risk (HR 0.71; P<0.001).
AstraZeneca (NYSE:AZN) unveiled an expanded manufacturing facility in Coppell, Texas on October 15, 2025, backed by a $445 million investment to double Lokelma production for the US and global markets.
The expansion adds a 9,000 sq ft building, two novel manufacturing lines, upgraded labs, warehousing, utilities and administrative space. Coppell is the sole global Lokelma manufacturing site serving >50 countries and employs >250 people.
This project follows a recent groundbreaking in Virginia and is part of AstraZeneca’s announced $50 billion US R&D and manufacturing commitment over five years; the company reported creating approximately $20 billion of value to the US economy in 2025.
AstraZeneca (AZN) will present new clinical data at ESMO Congress, Oct 17–21, 2025, featuring first readouts from four major pivotal trials and more than 95 abstracts across approved and pipeline medicines.
Key highlights include Presidential Symposium presentations of DESTINY-Breast11 and DESTINY-Breast05 on ENHERTU in HER2-positive early breast cancer, primary results from TROPION-Breast02 on DATROWAY in metastatic TNBC, and POTOMAC and MATTERHORN results for IMFINZI in early bladder and gastric cancers. The program also features 26 oral presentations and data on multiple ADCs, IO bispecifics and combination regimens.
AstraZeneca (AZN) will increase investment in a new Virginia manufacturing facility to $4.5 billion, a $500m boost to expand capability to produce a broader range of medicines including weight‑management small molecules and antibody drug conjugate (ADC) cancer therapies.
The Rivanna Futures site in Albemarle County is expected to create approximately 3,600 jobs (about 600 ongoing skilled roles and 3,000 construction roles). Work starts immediately and the facility is expected to be operational in 4–5 years. The project is part of a $50 billion U.S. R&D and manufacturing commitment and will deploy AI, automation, and data analytics.